Berlin – September 07, 2026 -- Germany's largest pharmaceutical trade association, Pharma Deutschland, has warned that new cost-containment measures under the GKV-BStabG threaten drug supply, innovation, and investment in the country, even as it welcomes a fresh round of government dialogue on AMNOG reform.
Federal Ministry convenes stakeholders for September 3 dialogue
The Federal Ministry of Health has invited industry representatives to an in-depth discussion on Thursday, September 3, 2026, focused on harmonizing Germany's drug pricing and assessment framework. Pharma Deutschland, which represents roughly 400 member companies employing about 80,000 people in Germany, said it backs the continuation of the Pharma- und Medizintechnik Dialog but insists selective bureaucratic fixes cannot offset broader damage from recent legislation.
GKV-BStabG measures raise rebate burden on manufacturers
The GKV-Beitragssatzstabilisierungsgesetz introduced an increased manufacturer rebate, additional mandatory rebate contracts for patent-protected medicines, and tighter price-volume regulations within the AMNOG framework. Pharma Deutschland argues these instruments undermine the existing value-based pricing model, elevate supply risk for patients, and slow research and development investment tied to the German market.
Association demands more than harmonization to offset new rules
"To keep supplying patients with new drug therapies going forward requires more than long-overdue harmonization and selective bureaucratic relief," said Dorothee Brakmann, Managing Director of Pharma Deutschland. The association contends that the new regulatory changes effectively devalue the AMNOG system as a whole, regardless of procedural streamlining.
Triple review process burdens drugmakers with redundant assessments
Pharma Deutschland flagged that manufacturers currently must navigate three separate, resource-intensive procedures: the EU marketing authorization process, EU Health Technology Assessment (EU-HTA), and Germany's national AMNOG benefit assessment. The group specifically called for urgent alignment between regulatory authorities and the Gemeinsamer Bundesausschuss (G-BA) on how special therapy situations are evaluated, citing persistent discrepancies between the two bodies.